


Investing in the Future With **Biosimilars**

Explore the potential biosimilars may offer in alleviating financial stress across the health care system

Biologics accounted for almost half of all US drug spending in 2019.¹ **As rising costs continue to challenge the health care system, how can biosimilars help decrease costs and increase access?**



Is the full potential of biosimilars currently being realized? >

Reference: 1. Aitken M, Kleinrock M, Muñoz E. Biosimilars in the United States 2020–2024: competition, savings, and sustainability. IQVIA Institute for Human Data Science report. September 29, 2020. Accessed June 29, 2021. <https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2020-2024>



Addressing the Cost
of Biologics

Pursuing the Full Potential

Measuring the Impact
of Biosimilars

Looking to the Future

How can the health care system sustain the cost burden of **biologics**?

Biologics are essential medicines in the mitigation and treatment of many serious illnesses, including cancers and chronic conditions.^{1,2} Preserving access to these treatments is important as the need for them grows—since 2013, **there has been a dramatic increase in patients diagnosed with autoimmune conditions such as Crohn's disease, ulcerative colitis, psoriasis, and rheumatoid arthritis.**³

Biologics can be costly^{2,4}:

One example of how these high costs affect the health care system is nonadherence⁶:



In 2019, US spending on biologics reached **\$211 billion⁵**



A retrospective cohort analysis revealed **issues with cost contributed to RA patients stopping their medication**, particularly patients on Medicare⁶



A clear need for lower costs and greater access across the health care system is why the FDA passed the Biologics Price Competition and Innovation Act (BPCI Act).²

RA, rheumatoid arthritis; FDA, U.S. Food and Drug Administration.

Discover the impact adoption rates may have on the potential for benefits >

References: **1.** Mulcahy AW, Hlávka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. October 22, 2017. Accessed April 5, 2021. https://www.rand.org/content/dam/rand/pubs/perspectives/PE200/PE264/RAND_PE264.pdf **2.** Biosimilars Action Plan. Balancing Innovation and Competition. FDA website. July 2018. Accessed June 10, 2021. <https://www.fda.gov/media/114574/download> **3.** Aitken M, Kleinrock M. Medicine use and spending in the U.S.: a review of 2018 and outlook to 2023. IQVIA Institute for Human Data Science report. May 9, 2019. <https://www.iqvia.com/insights/the-iqvia-institute/reports/medicine-use-and-spending-in-the-us-a-review-of-2018-and-outlook-to-2023> **4.** Atzinger CB, Guo JJ. Biologic disease-modifying antirheumatic drugs in a national, privately insured population: utilization, expenditures, and price trends. *Am Health Drug Benefits*. 2017;10(1):27–36. **5.** Aitken M, Kleinrock M, Muñoz E. Biosimilars in the United States 2020–2024: competition, savings, and sustainability. IQVIA Institute for Human Data Science report. September 29, 2020. Accessed June 29, 2021. <https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2020-2024> **6.** Harnett J, Wiederkehr D, Gerber R, et al. Primary nonadherence, associated clinical outcomes, and health care resource use among patients with rheumatoid arthritis prescribed treatment with injectable biologic disease-modifying antirheumatic drugs. *J Manag Care Spec Pharm*. 2016;22(3):209–218. doi:10.18553/jmcp.2016.22.3.209



Addressing the Cost of Biologics

Pursuing the Full Potential

Measuring the Impact of Biosimilars

Looking to the Future

Biosimilars are currently being used less than a third of the time¹

Overall use of biosimilars has risen since the first biosimilars were approved in the United States, but **future savings from biosimilars may depend in part on their uptake by stakeholders.**^{1,2}



A lack of trust in using biosimilars may contribute to a **loss of savings potential**²



In response, educational efforts and leadership from health system pharmacists may help stakeholders **adopt biosimilars with more confidence**³



Overall, the potential for savings to the health care system may depend on how biosimilars are utilized moving forward.⁴

Learn how competition from biosimilars may help lower prices >

References: **1.** Aitken M, Kleinrock M. Medicine use and spending in the U.S.: a review of 2018 and outlook to 2023. IQVIA Institute for Human Data Science report. May 9, 2019. Accessed October 11, 2020. <https://www.iqvia.com/insights/the-iqvia-institute/reports/medicine-use-and-spending-in-the-us-a-review-of-2018-and-outlook-to-2023> **2.** Aitken M, Kleinrock M, Muñoz E. Biosimilars in the United States 2020–2024: competition, savings, and sustainability. IQVIA Institute for Human Data Science report. September 29, 2020. <https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2020-2024> **3.** Zlatkus A, Bixby T, Goyal K. Considerations for the US health-system pharmacist in a world of biosimilars. *Drugs Context*. 2020;9:2019-12-1. doi:10.7573/dic.2019-12-1 **4.** Mulcahy AV, Hlávka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. *Rand Health Q*. 2018;7(4):3.



Addressing the Cost of Biologics

Pursuing the Full Potential

Measuring the Impact of Biosimilars

Looking to the Future

Biosimilars offer a potential for greater savings and access across the health care system^{1,2}

What the FDA set in motion with the BPCI Act was the opportunity for competitive pricing from biosimilars to provide potential future savings to the health care system.^{1,2}

Since the passing of the BPCI Act:

As new biosimilars launch and existing biosimilars are embraced:



Biosimilars have contributed
\$37 billion
in estimated savings as of 2019³



Biosimilars have the potential to increase savings by
\$104 billion
from 2020–2024³



As competition increases from biosimilar adoptions, the potential for significant savings to the health care system increases as well.²

FDA, U.S. Food and Drug Administration; BPCI Act, Biologics Price Competition and Innovation Act.

Consider the potential for biosimilars in the years to come >

References: **1.** Biosimilars Action Plan. Balancing Innovation and Competition. FDA website. July 2018. Accessed June 10, 2021. <https://www.fda.gov/media/114574/download> **2.** Mulcahy AV, Hlávka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. *Rand Health Q.* 2018;7(4):3. **3.** Aitken M, Kleinrock M, Muñoz E. Biosimilars in the United States 2020–2024: competition, savings, and sustainability. IQVIA Institute for Human Data Science. September 29, 2020. Accessed June 29, 2021. <https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2020-2024>




Addressing the Cost of Biologics

Pursuing the Full Potential

Measuring the Impact of Biosimilars

Looking to the Future

Help the Future Evolve



In summary:

In 2019, biologics accounted for almost half of all US drug spending.¹ What impact might biosimilars have on the health care system?

- 1** The cost of biologics continues to rise and burden the health care system.²⁻⁴
- 2** A slow embrace of biosimilar adoption may hamper future savings potential.¹
- 3** The ultimate goal of biosimilars is to help potentially reduce costs and increase access across the health care system.^{2,5}

Will the full potential biosimilars may offer the health care system be realized? It may depend on the utilization of biosimilars moving forward.¹

[Download this guide to adopting biosimilars in your institution](#) ↓

[Download this guide to adopting biosimilars in your practice](#) ↓

References: **1.** Aitken M, Kleinrock M, Muñoz E. Biosimilars in the United States 2020–2024: competition, savings, and sustainability. IQVIA Institute for Human Data Science report. September 29, 2020. <https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2020-2024> **2.** Biosimilars Action Plan. Balancing Innovation and Competition. FDA website. July 2018. Accessed June 10, 2021. <https://www.fda.gov/media/114574/download> **3.** Atzinger CB, Guo JJ. Biologic disease-modifying antirheumatic drugs in a national, privately insured population: utilization, expenditures, and price trends. *Am Health Drug Benefits.* 2017;10(1):27–36. **4.** Aitken M, Kleinrock M. Medicine use and spending in the U.S.: a review of 2018 and outlook to 2023. IQVIA Institute for Human Data Science report. May 9, 2019. <https://www.iqvia.com/insights/the-iqvia-institute/reports/medicine-use-and-spending-in-the-us-a-review-of-2018-and-outlook-to-2023> **5.** Mulcahy AW, Hlávka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. *Rand Health Q.* 2018;7(4):3.

© 2021 Organon group of companies. All rights reserved. ORGANON and the ORGANON Logo are trademarks of the Organon group of companies. US-SBT-115123 08/21



**Addressing the Cost
of Biologics**

Pursuing the Full Potential

**Measuring the Impact
of Biosimilars**

Looking to the Future